Linezolid Stability in Peritoneal Dialysis Solutions

Golper T.A. , Brier M.E. , Bunke M. , Schreiber M.J. , Bartlett B.K. , Hamilton R.W. Risk factors for peritonitis in long-term peritoneal dialysis: The Network 9 peritonitis and catheter survival studies. Am J Kidney Dis 1996; 28: 428–36.

United States Renal Data System. USRDS 2000 annual report. Bethesda, MD: The National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases; 2000.

Fried L.F. , Bernardini J. , Johnston J.R. , Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2176–82.

Keane W.F. , Bailie G.R. , Boeschoten E. , Gokal R. , Golper T.A. , Holmes C.J. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update (Published erratum appears in Perit Dial Int 2000; 20: 828–9). Perit Dial Int 2000; 20: 396–411.

US Centers for Disease Control. Reduced susceptibility of Staphylococcus aureus to vancomycin — Japan. MMWR Morb Mortal Wkly Rep 1997; 46: 624–6.

US Centers for Disease Control. Staphylococcus aureus with reduced susceptibility to vancomycin — United States. MMWR Morb Mortal Wkly Rep 1997; 46: 765–6.

Smith T.L. , Pearson M.L. , Wilcox K.R. , Cruz C. , Lancaster M.V. , Robinson–Dunn B. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493–501.

Sieradzki K. , Roberts R.B. , Haber S.W. , Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus. N Engl J Med 1999; 340: 517–23.

Rotun S.S. , McMath V. , Schoonmaker D.J. , Maupin P.S. , Tenover F.C. , Hill B.C. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5: 147–9.

US Centers for Disease Control. Staphylococcus aureus with reduced susceptibility to vancomycin — Illinois. MMWR Morb Mortal Wkly Rep 1999. (Accessed 1/12/00) Available from: URL: http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/mm4851a1.htm.

Pharmacia & Upjohn. Package literature for Zyvox®. April 2000.

Dresser L.D. , Rybak M.J. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18: 456–62.

Matzke G.R. , Bailie G.R. Hemodialysis and peritoneal dialysis. In: Dipiro J.T. , Talbert R.L. , Yee G.C. , Matzke G.R. , Wells B.G. , Posey L.M. , eds. Pharmacotherapy: a Pathophysiologic Approach, 4th ed. Stamford, CT: Appleton & Lange; 1999: 795–821.

Bailie G.R. , Kane M.P. Stability of drug additives to peritoneal dialysate. Perit Dial Int 1995; 15: 328–35.

Li Z. , Willke R. , Pinto L.A. , Rittenhouse B.E. , Rybak M.J. , Pleil A.M. Comparison of length of hospital stay for patients with known or suspected methicillinresistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21: 263–74.